 | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Health Care & Policy |  |  | | - Lilly's dulaglutide outperforms widely used diabetes drugs in trials
Three late-stage trials indicate that patients injected with Eli Lilly and Co.'s experimental GLP-1 receptor agonist dulaglutide experienced sustained reductions in blood sugar and lost more weight compared with patients who took generic metformin, Bristol-Myers Squibb's Byetta and Merck & Co.s' Januvia. Lilly plans to submit dulaglutide for U.S. approval this year. Reuters (6/22)        | Too Big to Succeed: Where are Large Pharmas Heading?
The biopharmaceutical industry's largest companies have grown too large to offer shareholders a compelling return. L.E.K.'s analysis shows how pharma companies can address their most pressing challenges, including key internal issues such as scale as a core foundation of their growth aspirations.
Download the free whitepaper. |
 | Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Enerkem gets $48.2M boost to scale up waste-to-ethanol process
Canada's Enerkem, which canceled a planned initial public offering last year, has secured $48.2 million in new financing. The company will use the funds to scale up its waste-to-ethanol production process. The new funds came from Investissement Quebec and existing investors, including Waste Management, Braemar Energy Ventures and The Westly Group. Bloomberg (6/20) | News from BIO | | | | - April 2013 BIO therapeutic newsletters
The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access our April 2013 Therapeutic Newsletters. Should you have any comments or questions, please contact Charles Crain.
| SmartQuote | | | |  | Above all be of single aim; have a legitimate and useful purpose, and devote yourself unreservedly to it."
--James Allen,
British writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, June 21, 2013
- Thursday, June 20, 2013
- Wednesday, June 19, 2013
- Tuesday, June 18, 2013
- Monday, June 17, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment